On October 1, 2014, Russell H. Plumb became Chairmen, Director. Previously, Mr. Plumb served as President and Chief Executive Officer from November 2012 to September 2014.
Mr Plumb served as President, Chief Executive Officer and Chief Financial Officer of Inhibitex Inc., a US publicly-traded, clinical-stage drug development company, from December 2006 through February 2012, when it was acquired by Bristol-Myers Squibb for approximately $2.5 billion. Prior to its acquisition, Inhibitex focused its resources in recent years on developing antiviral, small molecules, including compounds to treat hepatitis C virus (HCV). From 2000 to December 2006, Mr Plumb was the Chief Financial Officer of Inhibitex, during which time he oversaw numerous financing transactions, including the company’s initial public offering in 2004.
Mr Plumb has received designations as a certified public accountant in Michigan and Georgia. Mr Plumb received both a BComm and an MBA from the University of Toronto.